Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2014 09:15 ET | Source: Repros Therapeutics Inc.

Repros Reports Findings From the Six Month Study of Androxal(R) in Men With Secondary Hypogonadism

Greater Than 80% of Men Obtained T in the Normal Range Evidence of Continued Benefit After Treatment Withdrawal THE WOODLANDS, Texas, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics...
February 06, 2014 00:22 ET | Source: Repros Therapeutics Inc.

Repros Meets With FDA to Discuss Data Requirements for Androxal(R) in the Treatment of Secondary Hypogonadism

NDA submission remains anticipated by year end 2014 No additional long-term safety assessments currently planned before NDA submission and review THE WOODLANDS, Texas, Feb. 6, 2014 (GLOBE...
January 08, 2014 09:15 ET | Source: Repros Therapeutics Inc.

Repros Initiates Two Head to Head Studies of Androxal(R) Versus the Leading Topical Testosterone Gel

Studies designed to compare performance of Androxal to testosterone (T) replacement in restoring and maintaining normal testicular function Anticipated to expand Androxal label and thereby...
December 19, 2013 16:17 ET | Source: Repros Therapeutics Inc.

Repros Adds Marketing and Commercialization Expertise to Board of Directors

THE WOODLANDS, Texas, Dec. 19, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has added Michael Suesserman to the Company's Board of Directors. Michael...
November 25, 2013 15:00 ET | Source: Repros Therapeutics Inc.

Repros to Present Data on the Benefits of Testosterone Restoration With Androxal(R) Compared to T Replacement With Gels at 9th Men's Health World Congress

THE WOODLANDS, Texas, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported it will deliver an invited podium presentation at the 9th Men's Health World...
November 25, 2013 06:59 ET | Source: Repros Therapeutics Inc.

FDA Schedules Face to Face Meeting With Repros to Discuss Androxal(R) Efficacy

THE WOODLANDS, Texas, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported it has been granted a face to face meeting with the FDA to discuss the pivotal...
November 07, 2013 09:15 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Reports Third Quarter 2013 Financial Results

THE WOODLANDS, Texas, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2013. Liquidity and...
November 04, 2013 16:05 ET | Source: Repros Therapeutics Inc.

Repros Receives FDA Guidance for Proellex(R) Low Dose Oral Uterine Fibroid Clinical Program

Company Instructed to Request Lifting of Full Clinical Hold for Oral Proellex for the Treatment of Uterine Fibroids Oral Study to be Conducted in Parallel to Vaginal Phase 2b Study THE...
October 22, 2013 20:00 ET | Source: Repros Therapeutics Inc.

Repros Receives FDA Guidance For Androxal(R) Clinical Program

FDA instructs Repros to request meeting to discuss adequacy of studies ZA-301 and ZA-302 as evidence of pivotal efficacy FDA will now consider label claims versus approved testosterone...
October 07, 2013 10:25 ET | Source: Repros Therapeutics Inc.

Repros Announces Three Studies Accepted for Presentation at the Annual Meeting of the Sexual Medicine Society of North America

Presentation Titles Include: Oral Enclomid (Androxal®) Raises Free and Total Serum Testosterone in Hypogonadal Men: Comparison with a Topical Gel Oral Enclomid (Androxal®)...